Last reviewed · How we verify
Vorinostat, capecitabine, and cisplatin
At a glance
| Generic name | Vorinostat, capecitabine, and cisplatin |
|---|---|
| Also known as | Zolinza, and xeloda |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vorinostat, capecitabine, and cisplatin CI brief — competitive landscape report
- Vorinostat, capecitabine, and cisplatin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI